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Angiosarcoma 
The term angiosarcoma applies to a range of malignant endothelial vascular 
neoplasms, mimicking the morphologic and functional features of normal endo-
thelium, which can affect a variety of sites. Soft tissue angiosarcoma consists 
for the majority out of cutaneous tumors, and less than one quarter present as 
deep soft tissue tumor. [1] Angiosarcomas usually occur in adulthood, with a peak 
incidence in the seventh decade. The tumor is very uncommon and has a low 
prevalence worldwide. Several conditions are associated with the development 
of angiosarcomas, including neurofibromatosis (NF1) [2,3], adjacent to synthetic 
vascular grafts [4] and following radiation therapy. 
Among angiosarcomas, the location at the breast forms a special subgroup. Two 
main groups are described: primary angiosarcomas and secondary angiosarco-
mas of the breast. Primary angiosarcomas account for less than 1% of all breast 
malignancies [5] and their peak incidence is in the third and fourth decade of 
life. Secondary angiosarcomas are further defined into two subgroups: angio-
sarcomas following longstanding lymphedema, known as Stewart Treves syn-
drome, and angiosarcomas following radiation therapy. Stewart Treves syndrome 
can develop in the lymph edematous arm as a consequence of breast cancer 
treatment with axillary nodal dissection and was firstly described by Stewart and 
Treves in 1948. [6] Since the treatment for early stage breast cancer has changed 
to a more conservative approach with lumpectomy and adjuvant radiation, less 
cases of Stewart Treves have been observed and more angiosarcomas in the 
radiated field. Patients treated for breast cancer with radiation have a five fold 
higher risk for angiosarcoma than patients not receiving radiation. [7] The clinical 
presentation differs between these two subgroups; angiosarcomas following radi-
ation develop earlier and have shorter symptom duration than the Stewart Treves 
tumors. [8] Radiation associated angiosarcomas of the breast will be further de-
scribed in the next chapter. 
A systematic review published in 2012, reported all literature about radiation as-
sociated sarcoma since 1970. [9] Focusing on the radiation associated sarcoma 
of the breast, the incidence is particularly low considering the long time span of 
the studies. The radiation dose to the breast as part of the conservative breast 
cancer treatment was median 53Gy. Previous studies have shown a dose related 
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risk of radiation induced sarcomas, starting upon as much as 14Gy. [10,11] The 
age at the time of diagnosis of radiation associated sarcoma was median 68 
years, and the latency period between the treatment of breast cancer and the 
diagnosis of radiation induced sarcoma was median 9 years.  The relative long la-
tency period at which radiation associated sarcoma of the breast develop implies 
a long follow up in the hospital or at least a good self examination by the patient.
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